Article info

Download PDFPDF
Safety and tolerability of subcutaneous trastuzumab and intravenous pertuzumab as adjuvant treatment for HER2 positive breast cancer: a pilot study

Authors

  1. Correspondence to Dr Joanne Chiu, Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong; jwychiu{at}hku.hk
View Full Text

Citation

Wong CY, Leung R, Kwok GW, et al
Safety and tolerability of subcutaneous trastuzumab and intravenous pertuzumab as adjuvant treatment for HER2 positive breast cancer: a pilot study

Publication history

  • Received April 20, 2021
  • Accepted May 17, 2021
  • First published May 26, 2021.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.